New dosing strategy aims to reduce eye side effects in myeloma treatment

NCT ID NCT07614360

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple myeloma who have had at least two prior treatments will be randomly assigned to different dosing regimens. The study will compare eye side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin, bortezomib, and dexamethasone
What this could lead to: If successful, this could lead to a safer and more effective dosing schedule for this combination therapy, potentially improving outcomes for people with relapsed multiple myeloma.
What could go wrong: This is a phase 2 trial with only 150 participants, so results may not apply to everyone. The drug combination can cause serious eye problems, and alternative dosing may not reduce this risk or maintain effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.